SUMMARY The clinical efficacy of intravenous amiodarone in terminating sustained ventricular tachycardia and in preventing recurrences of ventricular tachycardia and ventricular fibrillation was evaluated in 26 patients. All of them presented with organic heart disease accompanied by depressed left ventricular function. Intravenous amiodarone terminated spontaneous ventricular tachycardia in eight of 19 patients. Fifteen of the 26 patients had had at least one episode of ventricular tachycardia or ventricular fibrillation each day in the period immediately before the intravenous administration of amiodarone. Amiodarone controlled ventricular tachycardia or ventricular fibrillation in nine of these 15 patients; in three further cases it was successful when supplemented by additional administration of a previously ineffective antiarrhythmic drug and ventricular pacing. Two patients died despite these measures. In one, the amiodarone infusion had to be stopped because of an arrhythmogenic effect. Sustained deterioration of haemodynamic function or of pre-existing intraventricular conduction disturbances was never seen.
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Intravenous amiodarone was effective in terminating sustained ventricular tachycardia and in preventing frequent episodes of ventricular arrhythmia that were refractory to other antiarrhythmic drugs.
Long term treatment with oral amiodarone is effective in ventricular tachycardia and ventricular fibrillation refractory to conventional antiarrhythmic drugs.`' Prolonged administration is required to achieve these antiarrhythmic effects, and oral amiodarone is not an appropriate treatment for acute tachycardia.4 Intravenous amiodarone, however, had a rapid effect on supraventricular tachycardias.56 Its role in the short term treatment of life threatening ventricular arrhythmias has not yet been determined. We report the results of using intravenous amiodarone for the termination and short term control of recurrent sustained ventricular tachycardia and ventricular fibrillation.
Patients and methods
We treated 26 patients ( This proved unsuccessful, however, and an antitachycardia pacemaker had to be implanted. Coronary bypass surgery and an aneurysmectomy were performed in the other two and in the patient who showed an arrhythmogenic effect in response to amiodarone.
The following side effects were seen: thrombophlebitis on seven occasions, flush once, sinus arrest after electrical cardioversion once, and an increase of arrhythmia once. In the patient with the sinus arrest a normal sinus rhythm was restored immediately after the intravenous administration of 1 mg atropine. Hypotension, which we saw five times during short term infusion, and persistent ventricular tachycardia were rapidly eliminated by cardioversion. Table 3 shows that the RR and PR intervals were not affected by intravenous amiodarone. Neither was the QTc time nor the QRS duration. Eleven of the 26 patients had conduction disorders before the intravenous administration of amiodarone: first degree atrioventricular block in three cases, right bundle branch block in two, and a left bundle branch block in two. Two further patients had an incomplete right bundle branch block, and two an incomplete left bundle branch block. Intravenous amiodarone, however, never caused a deterioration in atrioventricular or intraventricular conduction in any of the 11 patients with pre-existing conduction disorders, neither did it provoke new disturbances of this type in any of the remaining 15 patients.
ELECTROCARDIOGRAPHIC FINDINGS

SERUM CONCENTRATIONS OF AMIODARONE AND DESETHYL AMIODARONE CONCENTRATION (figure 1)
In three patients the serum concentrations of amiodarone and desethyl amiodarone were measured immediately before and after the short term infusion. They were also measured every two hours during the 24 hour intravenous treatment. Serum concentrations of amiodarone reached an initial peak of between 4 9 and 7-8 gg/ml immediately after the short term infusion. During the succeeding period of observation they ranged from 0-5 to 1-5 g/ml. Concentrations of desethyl amiodarone, however, behaved differently. In one patient this metabolite was found four hours after treatment started, but in the remaining two it was never detected during the intravenous infusion.
Discussion
This study shows that intravenous amiodarone can be used safely and effectively for the short term control of frequent recurrent ventricular tachycardia and ventricular fibrillation and also for the termination of sustained ventricular tachycardia. The rate of termination in our patients-eight out of 19-is lower than the average of 70% in other reports.'
This discrepancy is primarily the result of different rates ofamiodarone administration. We started treatment with a short term infusion rather than a bolus, which occasionally results in severe complications.4
In five patients in whom persistent ventricular tachycardia was rapidly corrected by cardioversion, hypotension occurred during short term infusion of amiodarone. Therefore close supervision and continuous monitoring not only of the electrocardiogram but also of blood pressure are recommended during intravenous amiodarone administration.
Of greater clinical significance than the termination of sustained ventricular tachycardia is the prompt efficacy with which amiodarone prevented ventricular tachycardia and ventricular fibrillation in 369 370 Schutzenberger, Leisch, Kerschner, Harringer, Herbinger our patients. Thus intravenous amiodarone on its own controlled tachycardia in nine of the 15 patients with frequent attacks of ventricular tachycardia or ventricular fibrillation that were refractory to other antiarrhythmic drugs. In addition three further patients were stabilised by supplementary administration of a previously ineffective antiarrhythmic drug and ventricular pacing. Similar positive results were also reported by Morady et al, who treated their patients mainly by repeating a bolus,"0 and by Saksena et al, who performed continuous infusions for 4-7 days." Blood concentrations ofamiodarone at the dosage we chose tend to be at the lower end of the range generally regarded as therapeutically effective. Therefore an increase of the dose infused over 24 hours might be expected to lead to better results, especially in patients with frequent attacks.
Only occasionally during the treatment with intravenous amiodarone did serious side effects occur that required the treatment to be stopped or the application of additional measures. The augmentation of the arrhythmias seen in one patient started 30 minutes after the start of treatment and persisted for about an hour after interruption of the infusion. This arrhythmogenic effect was not accompanied by a QTc prolongation, although such a correlation has been reported during oral amiodarone.'2" During the sinus arrest which occurred after cardioversion a supraventricular escape rhythm and a fall in blood pressure were seen. The immediate intravenous administration of 1 mg atropine resulted in rapid restoration of sinus rhythm and normalisation of blood pressure. A few weeks before this patient showed normal sinus node function in a follow up electrophysiological study. Although a sinus arrest was reported to have been induced by intravenous amiodarone in one instance, the cause of the arrest in our case cannot be clearly attributed to the drug, because bradycardia seems to occur in 25% of all ventricular arrhythmias treated by cardioversion. 4 15 All our patients showed depressed left ventricular function and some of them had severe congestive heart failure. Nevertheless we never saw a lasting deterioration of cardiac output. Others had confirmed that intravenous amiodarone is well tolerated provided bolus doses are avoided.'°0 In our patients we found no alterations in the surface electrocardiogram during the 24 hour infusion of amiodarone. This observation was also reported by Wellens et 18 Because a QTc prolongation cannot be detected during short term intravenous amiodarone administration, the short term effect in intravenous administration seems to be based upon the inhibition of the rapid inward sodium current, which was shown especially during acute superfusion with the drug in previously untreated papillary muscles by Mason et al."9 An effect of amiodarone on the rapid inward sodium current was also suggested earlier by Coumel and Bouvrain' and Surawicz.21 Neither the short term infusion nor the subsequent 24 hour intravenous administration of amiodarone led to a deterioration of the atrioventricular or intraventricular conduction in any of our patients. This also held true when there was a pre-existing conduction disorder. Because ofthe effect of the drug on the atrioventricular node it should only be given after insertion of a pacemaker lead in patients with atrioventricular block.
LIMITATIONS OF THE STUDY
Because amiodarone was administered intravenously in all 26 patients we are not able to make a statement about the efficacy of this drug compared with that of other intravenously administered antiarrhythmics. A controlled comparative study, however, is impracticable because it would not be acceptable to stop a successful treatment in critically ill patients. Because all 26 patients were treated with other antiarrhythmic agents until just before the start of intravenous treatment, an additive effect cannot be ruled out. None the less, these antiarrhythmic agents were not effective when administered alone.
Intravenous amiodarone treatment with the specified dosage is effective both in the termination of sustained ventricular tachycardia and in the acute control of frequently recurring ventricular tachycardia and ventricular fibrillation that are refractory to treatment with other antiarrhythmic agents. With appropriate monitoring intravenous amiodarone can be used safely even in patients with left ventricular dysfunction and intraventricular conduction disturbances.
